To the Editor
=============

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a cure for patients with severe aplastic anemia (SAA). However, complications such as graft failure and graft-versus-host disease (GVHD) have limited the application of allo-HSCT\[[@B1],[@B2]\]. Increasing the number of donor blood stem cells decreases graft failure, however, high-dose of blood stem cell transplantation also increases the incidence of GVHD\[[@B3]\]. A combination of un-manipulated marrow and T-cell depleted PBSC as the stem cell source for SAA have shown rapid engraftment without increasing the risk of GVHD \[[@B4],[@B5]\]. Here, we report that transplantation of un-manipulated peripheral blood stem cells (PBSC) combined with bone marrow stem cells (BMSC) in patients with SAA to reduce the incidence of graft failure without negative effects on GVHD.

Fifteen SAA patients, received HLA- 6/6-identical sibling G-CSF-mobilized PB plus BMSC transplantation (Table [1](#T1){ref-type="table"}). CY/ALG (12/15 patients) or Flu/CY/ALG (3/15 patients) were used as conditioning regimen for all of them. CsA-MMF regimen was used to prevent aGVHD. Other supportive treatment were also given, such as *a*cyclovir, intravenous rhG-CSF, and intravenous immunoglobulin. The engraftment of transplant cells was determined using the following methods: STR-PCR analysis, Y PCR analysis, and tests for hematopoietic reconstitution and GVHD.

###### 

Outcome of 15 SAA patients who received the PB+BM transplantation

  No.              Disease   Conditioning Regimen   GVHD Prophylaxis                           Cell number                                Engraftment (days)                                                                          
  ---------------- --------- ---------------------- ------------------------------------------ ------------------------------------------ -------------------- ------------------ ---------------- ---- --- ----------------- ------- ------------
  1                VSAA-I    CY/ALG                 CsA+MMF                                    5.95/3.06                                  3.07/0.89            11                 15               18   N   skin              80^+^   
  2                VSAA-I    CY/ALG                 CsA+MMF                                    2.47/1.9                                   2.39/0.7             11                 14               18   N   N                 62^+^   
  3                SAA-II    CY/ALG                 CsA+MMF                                    2.91/2.6                                   2.33/1.48            15                 47               53                         7       Late graft
                                                                                                                                                                                                        N   N                         Rejection
  4                VSAA-I    CY/ALG                 CsA+MMF                                    2.46/2.21                                  5.66/0.95            14                 22               34   N   N                 54^+^   
  5                SAA-I     CY/ALG                 CsA+MMF                                    6.47/1.88                                  5.3/0.47             10                 20               50   N   N                 9       Infection
  6                SAA-I     CY/ALG                 CsA+MMF                                    4.54/3.87                                  2.81/1.1             12                 20               32   N   N                 46^+^   
  7                VSAA-I    CY/ALG                 CsA+MMF                                    6.17/1.0                                   1.54/0.3             14                 30               35   N   N                 30^+^   
  8                SAA-I     CY/ALG                 CsA+MMF                                    4.64/1.86                                  4.45/0.71            11                 15               18   N   N                 30^+^   
  9                SAA-II    Flu/CY/ALG             CsA+MMF                                    5.05/1.14                                  1.36/0.33            12                 17               20   N   N                 29^+^   
  10               SAA-II    Flu/CY/ALG             CsA+MMF                                    3.75/1.47                                  4.2/0.66             12                 15               16   N   N                 28^+^   
  11               SAA-I     CY/ALG                 CsA+MMF                                    2.98/1.77                                  6.62/0.9             10                 15               20   N   N                 26^+^   
  12               VSAA-I    CY/ALG                 CsA+MMF                                    7.80/2.6                                   5.7/0.85             12                 14               15   N   N                 26^+^   
  13               SAA-II    Flu/CY/ALG             CsA+MMF                                    5.86/2.1                                   5.03/0.92            13                 16               16   N   N                 20^+^   
  14               VSAA-I    CY/ALG                 CsA+MMF                                    2.15/1.9                                   0.49/1.14            23                 27               35   N   N                 5       Infection
  15               SAA-I     CY/ALG                 CsA+MMF                                    8.3/0.77                                   1.66/0.17            16                 29               48   N   N                 7^+^    
  Median (range)                                    4.64(2.15-8.3)/1.9(0.77-3.87) × 10^8^/kg   3.07(0.49-6.62)/0.85(0.17-1.48) × 106/kg   Day 12 (10-23)       Day 16.5 (14-47)   Day 20 (15-53)            Month 27 (7-80)           

CY: cyclophosphamide; ALG: antihuman T-lymphocyte globulin; MMF: mycophenolate mofetil; CsA: cyclosporine A; N: without any acute GVHD or chronic GVHD

All fifteen patients receiving allo-HSCT had successful bone marrow engraftment except for one of them had a late rejection. The incidence of acute and chronic GVHD was 0% and 6.67%. The reasons for the decreased incidence may be multifactorial, the use of G-CSF mobilized PBSC + BMSC~S~as the source of grafts, usage of ALG in conditioning regimen and CsA/MMF for the prophylaxis of GVHD. No recipients died from treatment-related complications within the first 100 days after transplantation. There were twelve disease-free survivals. The total three-year probability of disease-free survival was 79.8% (Figure [1](#F1){ref-type="fig"}).

![**Kaplan-Meier estimates overall survival rate of SAA patients treated with CsA and MMF after bone marrow and peripheral blood stem cell translantation from HLA-matched donors**.](1756-8722-3-51-1){#F1}

Our data indicate that high- dose of HSCT with both G-CSF mobilized PB and BMSCs resulted in a quick engraftment, low graft rejection, a relatively low incidence of acute GVHD, and good DFS, although larger scale, prospective, and randomized studies are required to confirm these benefits.
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